Boston Scientific (BSX) Plunges to 52-Week Low as Wall Street Adjusts Forecasts Pre-Earnings

Key Takeaways

Table of Contents

BSX shares plummeted to a 52-week low of $60.54, representing a 35–36% decline year-to-date
Stifel reduced its price objective from $90 to $85 based on electrophysiology hospital purchasing trends before Q1 2026 results
First-quarter 2026 financial results scheduled for release on April 22, 2026
Several Wall Street firms continue recommending Buy/Outperform despite target reductions — RBC maintains $115 forecast, UBS at $105
InvestingPro identifies BSX as significantly undervalued with a Fair Value estimate of $76.66

Shares of Boston Scientific have experienced significant turbulence throughout 2026. The medical device manufacturer saw BSX hit a 52-week bottom of $60.54 on April 21, with current trading levels hovering between $60.43 and $60.99 — a dramatic decline from its peak of $109.50 recorded earlier.

Boston Scientific Corporation, BSX

This represents approximately a 36% year-to-date plunge, wiping out substantial value from the company’s $90.6 billion valuation.

Analyst Rick Wise from Stifel reduced his price objective on BSX to $85 from a previous $90 in anticipation of the first-quarter 2026 financial release scheduled for April 22, 2026. Despite the reduction, he maintained his Buy recommendation.

The adjustment stemmed from monthly electrophysiology (EP) hospital procurement information that Stifel tracks to forecast quarterly performance prior to official announcements.

January figures showed approximately 92% reporting completion, February reached around 85%, and March stood at roughly 60% — providing an incomplete yet substantial view of EP sales momentum.

According to this data, Stifel concludes that BSX’s Q1 US EP consensus sales projection of approximately $587 million falls “within the band of achievability.” While not enthusiastically optimistic, this assessment doesn’t signal major concern either.

Stifel conducted a comparative analysis with Johnson & Johnson and Abbott Laboratories, utilizing the identical EP procurement database to validate forecasted versus reported revenues. The research firm had previously identified potential downside exposure to US EP consensus figures before the last quarterly report using comparable methodology.

Wall Street Forecasts Remain Significantly Higher Than Trading Levels

Notwithstanding the negative market momentum, Wall Street analysts haven’t turned pessimistic. Truist Securities maintained its Buy recommendation while trimming its target to $90 from $92. The firm anticipates the cardiovascular division will expand 8.5% to 9% in the forthcoming announcement.

RBC Capital reaffirmed an Outperform recommendation with a $115 price objective following direct conversations with BSX management regarding expansion opportunities.

UBS preserved its Buy stance and $105 forecast after the CHAMPION-AF clinical trial data for the Watchman cardiac implant. The study achieved all primary and secondary objectives — a favorable result that UBS believes mitigates headline concerns.

However, there’s a complication. The Watchman product demonstrated a marginally elevated ischemic stroke incidence versus non-vitamin K antagonist oral anticoagulants (NOACs), which concerned certain market participants.

Piper Sandler retained its Overweight rating following discussions with a high-volume electrophysiologist who anticipates Watchman adoption will expand despite the stroke statistics.

Shares Identified as Trading Below Intrinsic Value

InvestingPro has designated BSX as among its most undervalued equities, establishing its Fair Value at $76.66 — approximately 27% higher than current market prices.

Revenue expansion has stayed robust, with BSX delivering nearly 20% growth throughout the last twelve months. On a fundamental basis, this isn’t a deteriorating enterprise — it’s an equity facing market pressure.

Market attention now shifts to April 22, when BSX unveils Q1 2026 financial results. That announcement will provide the first genuine indication of whether EP revenue performance matched what Stifel’s procurement data suggests is possible.

✨ Limited Time Offer